JPM 2021: Medtronic, Biogen, Edwards LifeSciences, Guardant Health, Illumina
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.
You may also be interested in...
Exec Chat: Illumina CMO Looks From Pandemic Boom To Future Where Genomics Is ‘Foundational’ To Health Care
Illumina’s chief medical officer Phillip Febbo discusses expanding use cases for gene sequencing, the firm’s planned introduction of new long-read sequencing technology Infinity, the status of its Grail acquisition, and additional plans for 2022.
Illumina’s moves into infectious disease testing and further into the clinical setting have been accelerated by the pandemic. The genomic sequencing company is also fast expanding its companion diagnostics oncology partnerships.
Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.